Is HE4 Superior over CA-125 in the Follow-up of Patients with Epithelial Ovarian Cancer?-Reference-Cited by-同舟云学术

Is HE4 Superior over CA-125 in the Follow-up of Patients with Epithelial Ovarian Cancer?

Published:2020-07-28 Issue:10 Volume:21 Page:1026-1033
ISSN:1389-4501
Container-title:Current Drug Targets
language:en
Short-container-title:CDT

Author:

El Bairi Khalid¹^ORCID,Afqir Said¹,Amrani Mariam²

Affiliation:

1. Faculty of Medicine and Pharmacy, Mohamed Ist University, Oujda, Morocco

2. Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco

Abstract

Notwithstanding important advances in the treatment of epithelial ovarian cancer (EOC), this disease is still a leading cause of global high mortality from gynecological malignancies. Recurrence in EOC is inevitable and it is responsible for poor survival rates. There is a critical need for novel effective biomarkers with improved accuracy compared to the standard carbohydrate antigen-125 (CA-125) for follow-up. The human epididymis protein 4 (HE4) is used for early detection of EOC (ROMA algorithm) as well as for predicting optimal cytoreduction after neoadjuvant chemotherapy and survival outcomes. Notably, the emerging HE4 is a promising prognostic biomarker that has displayed better accuracy in various recent studies for detecting recurrent disease. In this mini-review, we discussed the potential of HE4 as an accurate predictor of EOC recurrence.

Publisher

Bentham Science Publishers Ltd.

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Medicine

Reference71 articles.

1. Webb,PM.; Jordan,SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017; 41: 3-14. http://dx.doi.org/10.1016/j.bpobgyn.2016.08.006 PMID: 27743768

2. Bray,F.; Ferlay,J.; Soerjomataram,I.; Siegel,RL.; Torre,LA.; Jemal,A. Global cancer statistics. 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin

3. Yang,WL.; Lu,Z.; Bast,RC,Jr. The role of biomarkers in the ma-nagement of epithelial ovarian cancer. Expert Rev Mol Diagn. 2017; 17(6): 577-91. http://dx.doi.org/10.1080/14737159.2017.1326820 PMID: 28468520

4. El Bairi K, Kandhro AH, Gouri A.;et al. Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer. Cell On-col (Dordr). 2017a; 40(2): 105-18. http://dx.doi.org/10.1007/s13402-016-0309-1 PMID: 27981507

5. Qiao,N.; Li,H. The value of mesothelin in the diagnosis and follow-up of surgically treated ovarian cancer. Eur J Gynaecol Oncol. 2013; 34(2): 163-5. PMID: 23781590

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Raman Spectroscopy and AI Applications in Cancer Grading: An Overview;IEEE Access;2024

2. Hyponatremia as a Prognostic Factor in Advanced Stage Ovarian Cancer Patients;CHIRURGIA-BUCHAREST;2023

3. Mucins as Potential Biomarkers for Early Detection of Cancer;Cancers;2023-03-07

4. Biomarkers for Early Diagnosis of Ovarian Carcinoma;ACS BIOMATER SCI ENG;2022

5. Biomarkers for Early Diagnosis of Ovarian Carcinoma;ACS Biomaterials Science & Engineering;2022-06-28